OncoMatch/Clinical Trials/NCT05253495

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Is NCT05253495 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-hodgkin lymphoma.

Phase 2RecruitingNew York Medical CollegeNCT05253495Data as of May 2026

Treatment: DOC Group B · Pv-COMRAD 1 and 2 Group B · Pv-R-CYM 1 and 2 Group B · DOC Group C · MAD CPR 1 and 2 · Pv-R CYVE 1 and 2 · Pv-R CYVE-MTX 1 and 2 · MAD CP · Pv-Cytarabine/etoposide · AD CP · Bv-AVD-R 1 and 2: COHORT IIa · Bv-NVD-R, Cycle 1-2 · Bv-NVD-R, Cycle 1-4 SER · Bv-AVD-R · Bv-NVD-R, Cycle 1-4 RER · Bv-NAVD-R, Cycle 1-2 — The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Hodgkin Lymphoma

Disease stage

Required: Stage I, IIA, IIB, IIIA, IIIB, IV, III

COHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration) COHORT Ib: any CNS involvement and/or BM involvement (≥ 25% lymphoma cells) COHORT IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK) COHORT IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)

Prior therapy

No prior treatment (treatment-naive required)

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Alabama · Birmingham, Alabama

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify